Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Isopropyl Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SNCA | P37840 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isopropyl Alcohol SCHEMBL19949927 | 0.98 | LMNA (0.50) | GAALMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL8462068 | 0.95 | GAA (0.52) | GAALMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL11027526 | 0.95 | GAA (0.52) | GAALMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL10935937 | 0.93 | LMNA (0.50) | GAALMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL11676297 | 0.93 | GAA (0.54) | GAALMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL1274859 | 0.91 | CYP2D6 (0.51) | GAALMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL11432043 | 0.91 | GAA (0.62) | GAALMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL34 | 0.91 | GAA (0.62) | GAALMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL31313 | 0.91 | GAA (0.62) | GAALMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL1705904 | 0.91 | GAA (0.62) | GAALMNAALDH1A1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112851506-B | Industrial preparation method of 3, 5-dimethoxy-4-alkyl benzyl alcohol | 湖北英纳氏生物科技有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-112851506-A | Industrial preparation method of 3, 5-dimethoxy, 4-alkyl benzyl alcohol | 湖北英纳氏生物科技有限公司 | 2021-05-28 | — | — | CN | claimed |
| US-12605471-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2026-04-21 | — | — | US | disclosed |
| CN-114989103-B | Preparation method of 2-methoxy-3- (1-methyl-1H-1, 2, 4-triazole-3-yl) aniline | 杭州科巢生物科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240058480-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | THE GENERAL HOSPITAL CORPORATION | 2024-02-22 | — | — | US | disclosed |
| US-11801316-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2023-10-31 | — | — | US | disclosed |
| CN-112851506-B | Industrial preparation method of 3, 5-dimethoxy-4-alkyl benzyl alcohol | 湖北英纳氏生物科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-112851506-B | Industrial preparation method of 3, 5-dimethoxy-4-alkyl benzyl alcohol | 湖北英纳氏生物科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-11666669-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2023-06-06 | — | — | US | disclosed |
| CN-114989103-A | Preparation method of 2-methoxy-3- (1-methyl-1H-1, 2, 4-triazole-3-yl) aniline | 杭州科巢生物科技有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-112851506-A | Industrial preparation method of 3, 5-dimethoxy, 4-alkyl benzyl alcohol | 湖北英纳氏生物科技有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090047588-A1 | PHOTOSENSITIVE MEMBER HAVING AN OVERCOAT | XEROX CORPORATION (US) | 2009-02-19 | — | — | US | disclosed |
| EP-1947101-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2008-07-23 | — | — | EP | disclosed |
| CN-101076519-A | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL IND LTD (JP) | 2007-11-21 | — | — | CN | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
| CN-1575191-A | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER PROD INC (US) | 2005-02-02 | — | — | CN | disclosed |
| WO-1995004052-A1 | METHYLGUANIDINE DERIVATIVES, METHODS FOR PREPARING SAME AND COMPOSITIONS CONTAINING SAID DERIVATIVES | SANOFI (FR) | 1995-02-09 | — | — | WO | disclosed |
| US-4308184-A | TEXTILES; ADHESION, SOFTNESS, SOLVENT RESISTANCE | BAYER AKTIENGESELLSCHAFT (DE) | 1981-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605471-B2 | Cromolyn derivatives and related methods of imaging and treatment | PSEN1, APP, PSEN2 | GAA 4063/4885LMNA 233/4885ALDH1A1 3176/4885 |
| US-11801316-B2 | Cromolyn derivatives and related methods of imaging and treatment | PSEN1, PSEN2, CROCC | GAA 1308/4885LMNA 62/4885ALDH1A1 3040/4885 |
| US-20240058480-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | PSEN1, PSEN2, CROCC | GAA 1525/4885LMNA 45/4885ALDH1A1 3053/4885 |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | GAA 2220/4885LMNA 1745/4885ALDH1A1 2047/4885 |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, THPO, PTAFR | GAA 1382/4885LMNA 1887/4885ALDH1A1 973/4885 |
| US-11666669-B2 | Cromolyn derivatives and related methods of imaging and treatment | PSEN1, PSEN2, CROCC | GAA 1525/4885LMNA 45/4885ALDH1A1 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.